Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
PushButton AI Team ·
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
You bought an AI tool. Nobody used it. $200/month quietly draining while the tab stays open.
You're not tech-stupid. You're just surrounded by people selling solutions before understanding your probl
You bought an AI tool. Nobody used it. $200/month quietly draining while the tab stays open.
You're not tech-stupid. You're just surrounded by people selling solutions before understanding your problem.
Here's what a pharma company quietly did that most business owners miss: they separated their AI assets into an independent entity. Not to impress investors. To get clarity. One focused application, one measurable purpose, one team responsible for results.
That's the real lesson. AI stops working when it's trying to do everything for everyone. It starts working when it's assigned one specific job inside your business.
The companies winning with AI right now aren't using more tools. They're using fewer — but with ruthless focus on a single problem worth solving.
This week, pick your one most repetitive, time-consuming task. Not your biggest problem. Your most boring one. That's where your first AI win lives. No new systems. No team overhaul. Just one targeted test with a clear outcome you can measure in 30 days.
Small proof beats big promises every time.
What's the AI tool sitting unused in your business right now — and what problem were you actually hoping it would solve?
... market opportunity in AI-driven drug development,” continued Mr. Sharma. “Separating our withZeta.ai assets into an independent entity is intended ...
